World's largest Real-World CGM study aims to unlock diabetes management secrets
NCT ID NCT07681024
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This global registry study follows 5,000 people with diabetes who use a Dexcom continuous glucose monitor (CGM). Researchers will track changes in HbA1c, a key measure of blood sugar control, over time. The goal is to understand how CGM use affects diabetes management in real-world settings across different countries and diabetes types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dexcom continuous glucose monitor (CGM)
- What this could lead to
- If successful, this study could provide real-world evidence on how CGM use improves blood sugar control over time for different types of diabetes.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may vary by country and individual use patterns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Electric pulse therapy in the gut: a new hope for type 2 diabetes?
- Fat cell 'Messages' may harm blood vessels — can exercise or surgery stop them?
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could diabetes be silently damaging your hearing?
- Press play on better health: could recording doctor visits boost Self-Care in seniors?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses